

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102360 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: **PCT/IB02/02149**

(22) International Filing Date: 10 June 2002 (10.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
TO2001A000580 15 June 2001 (15.06.2001) IT

(71) Applicant (for all designated States except US): **PROFES-
SIONAL DIETETICS S.R.L.** [IT/IT]; Via F. Petrarca, 22,
I-20123 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CONTI, Franco**
[IT/IT]; Via della Spiga, 33, I-20121 Milano (IT). **DIO-
GUARDI, Francesco, Saverio** [IT/IT]; Via Manara, 15,
I-20122 Milano (IT).

(74) Agents: **BIZZI, Franco** et al.; c/o Buzzi, Notaro & An-
tonielli d'Oulx Srl, Via Maria Vittoria, 18, I-10123 Torino
(IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS BASED ON AMINO ACIDS FOR IMPROVING THE MYOCARDIAL VENTRICULAR FUNC-
TION IN PATIENTS SUFFERING FROM DIABETES

(57) Abstract: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50 % of threonine and lysine. Other essential amino acids are preferably also provided, in particular methionine, phenylalanine, histidine, tryptophan, as well as non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e., cystine and cysteine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20 % with respect to the other active ingredients, and less than 10 % for each single amino acid.



WO 02/102360 A2

- 1 -

"Compositions based on amino acids for improving the myocardial ventricular function in patients suffering from diabetes"

* * *

5 The present invention refers to compositions based on amino acids for improving the myocardial ventricular function in patients suffering from diabetes, in particular II type diabetes.

10 Experimental studies carried out on patients of the indicated type have shown, at myocardium level, a depression of the energetic metabolism, a reduction of the synthesis velocity and an increase of the proteins degradation. A general degradation of the mechanical function of the cardiac muscle derives from the above,
15 whose main pathogenic mechanisms are the reduced availability of energetic material and the presence of contractile proteins having low ATPase activity.

20 At present, no therapeutic approaches are known aimed at producing a noticeable improvement of the ventricular myocardial function in patients suffering from diabetes, in order to favorably influence the natural story of said patients, by retarding or preventing the appearance of cardiac insufficiency, which represents the main cause of morbidity and mortality
25 within said population of patients.

 The present invention has the aim of indicating an absolutely innovative therapeutic approach to the above mentioned problem.

30 Within this frame, a first aim of the invention is that of indicating compositions capable of determining a noticeable improvement of the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes.

35 A further aim of the invention is that of indicating compositions capable of determining, in patients of the

- 2 -

above type, a noticeable increase of the ventricular ejection fraction, at rest and at peak of the isometric exercise.

5 A further aim of the invention is that of indicating compositions capable of eliminating the reduction of the ventricular ejection fraction which, in patients suffering from diabetes, occurs during isometric strain.

10 The inventors arrived at the formulation of compositions based on amino acids, as per the enclosed claims which are an integral part of the present description, which prove to be particularly effective for the proposed purposes.

15 Said compositions, being provided either for oral and parenteral use, are characterized by comprising, as main active ingredients, the branched chain amino acids leucine, isoleucine and valine, up to 75% of all the amino acids or active ingredients being present, by expressing the value in molecular weights.

20 Preferably, the compositions according to the invention also comprise, as further active ingredients, threonine and/or lysine, where in particular threonine plus lysine are present up to 50% of all the amino acids or active ingredients being present, by expressing the value in molecular weights.

25 In case, the compositions can provide for, as further active ingredients, other essential amino acids, in particular methionine and/or phenylalanine and/or histidine and/or tryptophan, and non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e. cystine and cysteine).

30 Preferably, the sum of the amounts expressed in molecular weights of threonine and lysine is greater than the sum of the single amounts of the other essential amino acids being provided, but in any case lower than the sum of the single amounts of the branched chain amino

- 3 -

acids being provided. In addition, the amounts expressed in molecular weight of threonine and of lysine can be each greater than the single amounts of the other essential amino acids being provided, but in any case
5 lower than the single quantities of the branched chain amino acids being provided.

The compositions according to the invention can also comprise one or more further amino acids, with respect to those as previously indicated, the sum of which,
10 expressed in molecular weight, is preferably lower than 20% with respect to the active ingredients, and less than 10% for each single further amino acid.

It should be noticed that, in general terms, a mixture of amino acids particularly suitable for
15 nutritional use in humans should satisfy different requirements:

- the pH of the solution of the mixture should be substantially neutral, in order to prevent urinary calcium losses;
- 20 - the mixture should be safe, in respect to calcium balance (i.e.: with no urinary losses) and homocyst(e)ine production (i.e., preferably related to the amount of all amino acids, a strictly correct ratio of sulphur containing amino acids, with a ratio cyst(e)ine /
25 methionine of at least 2:1 on a stoichiometric basis).

In addition, the content of essential amino acids in the mixture should be preferably in an adequate ratio to fulfill real human nutritional needs (and this can be optimized by the co-operative adjunction of adequate and
30 small ratios of some non essential amino acids).

Within this frame, a preferred formulation of the compositions according to the invention, comprising essential amino acids (leucine, isoleucine, valine, threonine, lysine, methionine, phenylalanine, histidine,
35 tryptophan) and some non essential amino acids (tyrosine

- 4 -

and cyst(e)ine), in different but fixed and co-operative molar ratios among them, is the following one:

- branched chain amino acids leucine (40-60% in molecular weight), isoleucine (20-40% in molecular weight) and valine (20-40% in molecular weight), preferentially in a stoichiometric ratio 2:1:1 among them, covering from 30 to 60% of the weight of the whole mixture;

- threonine plus lysine, preferably in a molar ratio with the said branched chain amino acids between 20 and 50%, preferably in a threonine to lysine ratio in which lysine is from 10 to 50% more represented than threonine;

- the above said branched chain amino acids plus threonine and lysine, whose sum of the molecular weight is in a stoichiometric ratio of 50 to 70% of a mixture also comprising histidine and other amino acids, where histidine is present in molar fraction up to 50% of the following amino acids:

- cyst(e)ine (i.e., cystine and cysteine) and methionine, up to 50% of histidine (the ratio between cyst(e)ine and methionine should be preferably of 50 to 200% greater for cyst(e)ine in molar ratio),

- phenylalanine and tyrosine, in molar ratio up to 50% of histidine (in which tyrosine is preferably represented up to 50% of the molar weight of phenylalanine),

- tryptophan, up to 10% of the weight of all the other amino acids, on a molar weight basis.

It has to be noticed that any other amino acid can be added to the above formulation, without altering the expected effects, provided that the sum of the additional amino acids is in a percentage lower than 20% with respect to the other active ingredients (less than 10% for each single amino acid).

- 5 -

It should also be noticed that a significant characteristic of the above said formulation is that of having a pH in water solution comprised between 6.5 and 8.5, and therefore suitable for a safe oral or parenteral use, in humans or animals, according to needs. This feature prevents the excessive calcium urinary losses induced by protein sources of amino acids.

The effects of an amino acids mixture according to the above suggested formulation were the subject of a comparative study.

To this purpose, 18 patients suffering from II type diabetes mellitus were recruited (M/F 16/2, age 62 ± 6 years, body mass index (BMI) 27.4 ± 3.0 kg/m²). The average duration of the disease was 12 ± 8 years. Glycate haemoglobin was $8.2 \pm 0.8\%$. After the basal evaluation, patients were randomized at the treatment with a composition of amino acids according to the above said preferred formulation of the invention (12 g/die) or with placebo, for a period of 3 weeks. The treatment was subsequently exchanged and maintained for a further period of 3 weeks.

The analyzed main metabolic parameters were: glycaemia, insulinemia, C-peptide, free fatty acids (FFA), total and fractioned cholesterol, triglycerids and fibrinogen.

The left ventricular function was evaluated by means of 2D echocardiography, using a Hewlett-Packard Sonon 5500 system, with dedicated program for the execution of echo-stress methodologies and the quantification of ventricular images. The echocardiographic studies were encoded and blind analyzed, by two independent observers, without knowing the identity of the patient and the experimental condition. The echocardiographic analysis was carried out using a digital cine-loop method (Prevue System, Nova Microsonics Inc.). The ventricular volumes

- 6 -

were calculated, in the various experimental conditions, with a biplane area-length method, from which the ejection fraction (EF) was derived as index of ventricular pump function: $EF = VTD - VTS / VTD$, wherein
5 VTD and VTS represent the telediastolic and telesistolic volume of the left ventricle, respectively.

The parietal contractile function was evaluated by analyzing the myocardium systolic thickening, in each segment obtained by subdividing the left ventricle into
10 16 segments (according to the American Society of Echocardiography standards) and by using a semiquantitative score system (1=normal, 2=hypocinesia, 3=akinesia, 4=dyscinesia).

The general and regional ventricular function was
15 studied at rest conditions and during isometric strain through *hand-grip test*.

After having determined the maximal voluntary contraction by means of a dynamometer, an isometric strain at 40% was carried out for 3 minutes. During
20 strain, ventricular function was monitored by 2D echocardiography and the arterial pressure was monitored through a continuous oscillometric method (Nippon Colin Co. Ltd).

The results of the study are expressed as mean \pm SD.
25 The multiple comparisons were carried out by means of the two-way variance analysis for repeated measures, followed by the Fisher's test. A two-tailed value ≤ 0.05 as been considered as a significant one.

None of the metabolic parameters was significantly
30 modified, neither by the treatment with the amino acids mixture according to the invention, nor by the administration of placebo.

As it is apparent from Table 1 which follows, the treatment with the mixture according to the invention did
35 not brought to significant variations, concerning

- 7 -

glycaemia at fast, insulinemia and sensitivity to insulin considered through the *insulin tolerance test* technique.

Also concerning lipidic metabolism, no variations were observed in relation to total cholesterol, HDL, triglycerids, free fatty acids and Lp(a). In addition, no substantial modifications occurred concerning both pressure values and body mass index.

* * *

Table 1 - Clinical characteristics of patients

	Placebo	Invention	P
Demography			
Age (years)	62 ± 6		
Clinical characteristics			
Disease duration (years)	10 ± 7		
Body mass index (SD) (kg/m ²)	27 ± 3	27 ± 3	n.s.
Anti-hypertension treatment (%)	77%		
Systolic pressure (SD) (mm Hg)	151 ± 12	154 ± 17	n.s.
Diastolic pressure (SD) (mmHg)	84 ± 5	84 ± 6	n.s.
HbA1c (SD) (%)	8.7 ± 1.7	8.6 ± 1.6	n.s.
Insulinemia (SD) (µm/ml)	14 ± 8	20 ± 15	n.s.
Cholesterolemia (SD) (mg/dl)	225 ± 27	214 ± 24	n.s.
HDL cholesterol (SD) (mg/dl)	47 ± 13	46 ± 15	n.s.
Triglyceridemia (SD) (mg/dl)	165 ± 91	115 ± 66	n.s.
Free fatty acids (SD) (µmol/l)	699 ± 395	656 ± 370	n.s.
Lp(a) (SD) (mg/dl)	12 ± 10	13 ± 10	n.s.
Proteinuria (mg/die)	40 ± 35	45 ± 29	n.s.
Anti-diabetes therapy (D/ADO/ADO+I/I)	2/9/3/4		

* * *

By analyzing the general ventricular function of the patients being the subject of the study, it was possible to draw the following conclusions:

1) the treatment with the amino acids mixture according to the invention does not modify, in a significant manner, the ventricular dimensions (considered as telediastolic volume), neither at rest (77

- 8 -

± 24 vs. 78 ± 24 ml/m², p=ns), nor at the peak of the isometric strain (46 ± 26 vs. 88 ± 25 ml/m², p=ns). In addition, the same increment induced by the isometric strain is maintained;

5 2) during treatment with the amino acids mixture according to the invention, the ejection fraction increases in a significant manner, both at rest (58 ± 8 vs. $52 \pm 12\%$, p=0.009) and at the peak of the isometric strain (58 ± 10 vs. 43 ± 13 , p=0.0001); it is then
10 particular interesting that

3) the reduction of the ejection fraction during isometric effort is abolished, with respect to the basal condition (p=0.188), which is instead maintained during placebo (p<0.0001).

15 Upon analyzing the regional myocardial contractile function of the patients, the following remarks are possible:

- the administration of the amino acids mixture according to the invention determines a reduction of the
20 extension of the regional contractile dysfunction at rest (considered as *wall motion score index*, WMSI) (1.32 ± 0.42 vs. 1.26 ± 0.41 , p=0.005);

- the isometric strain causes an extension of the regional contractile dysfunction independently of the
25 type of treatment, but the extension of the contractile dysfunction at the strain peak is smaller during the treatment with the amino acids mixture according to the invention (1.49 ± 0.45 vs. 1.29 ± 0.41 , p<0.05).

It results clear from the above that the oral
30 administration of the amino acids mixture according to the invention determines remarkable variations of the myocardial and ventricular function in diabetes patients, in particular II type diabetes.

Said administration has in fact positively
35 influenced the left ventricular myocardial function, both

- 9 -

at rest and during isometric strain. The fact is particularly interesting that said administration prevents the depression of the function caused by isometric strain which characterizes diabetes patients.

5 The above data also highlight a positive action on myocardial inotropism and contractile recruitment during conditions of increased load (such as during *hand grip* characterized by an acute increase of the postload). This effect can be the result of the combined action of an
10 improvement of the energetic metabolism and an inversion of the *shift* of the synthesis of contractile proteins to the production of fast ATPase activity elements.

 The results deriving from the study of the regional contractile function also highlight a reduction of the
15 extension of the reversible chronic contractile dysfunction, which is a sign of a favorable influence on hibernating myocardium.

 Finally, the administration of the amino acids mixture according to the invention reduces the further
20 extension of the contractile dysfunction induced by acute ischemia during isometric strain.

 From the given description the features of the present invention are clear, as well as its advantages. In particular, the oral administration of the described
25 mixture of amino acids positively influences the myocardial ventricular function of patients suffering from diabetes, in particular II type diabetes. The positive influence is evident either at rest and during the acute overload imposed by an isometric strain during
30 *hand-grip*, and also on the parietal contractile function, by means of a reduction of the extension of myocardial hibernation phenomena and of the extension of the contractile dysfunction induced by acute ischemia during isometric strain.

35 It results therefore clear that the proposed

- 10 -

treatment with amino acids allows for favorably influencing the natural story of diabetic patients, by retarding or preventing the appearance of cardiac insufficiency, which represents the main cause of
5 morbidity and mortality within said population of patients.

- 11 -

CLAIMS

1. Use of the branched chain amino acids leucine, isoleucine and valine as active ingredients for the manufacture of compositions for improving the myocardial
5 ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes.

2. Use, according to claim 1, wherein said branched chain amino acids are present up to 75% of the amino acids or active ingredients being provided, by expressing
10 the value in molecular weights.

3. Use, according to claim 1, wherein threonine and lysine are provided as further active ingredients.

4. Use, according to claim 3, wherein threonine plus lysine are present up to 50% of the amino acids or active
15 ingredients being present, by expressing the value in molecular weights.

5. Use, according to claim 3, wherein methionine and/or phenylalanine and/or histidine and/or tryptophan are provided as further active ingredients.

20 6. Use, according to claim 5, wherein tyrosine and/or cyst(e)ine are provided as further active ingredients.

7. Use, according to at least one of the previous claims, wherein the sum of the amounts in molecular
25 weights of threonine and lysine is greater than the sum of the single amounts of the other essential amino acids being provided, but lower than the sum of the single amounts of said branched chain amino acids.

8. Use, according to at least one of the previous
30 claims, wherein the amounts in molecular weight of threonine and of lysine are each greater than the single amounts of the other essential amino acids being provided, but lower than the single quantities of said branched chain amino acids.

35 9. Use, according to claim 6, wherein one or more

- 12 -

further amino acids are provided, the sum of which, in molecular weight, is in a percentage lower than 20% with respect to the other active ingredients, and less than 10% for each single further amino acid.

5 10. Compositions based on amino acids manufactured in accordance with one or more of claims 1 to 9, for use as a medicament in the improvement of the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes.

10 11. Composition, according to claim 10, characterized by comprising

- from 40 to 60% of leucine in molecular weight,
- from 20 to 40% of isoleucine in molecular weight,
- from 20 to 40% of valine in molecular weight,

15 preferentially in a stoichiometric ratio 2:1:1 among them, the sum of the amounts of branched chain amino acids leucine, isoleucine and valine being comprised between 30 to 60% of the sum in molecular weight of all the active ingredients being provided.

20 12. Compositions, according to claim 11, characterized by comprising threonine plus lysine in a molar ratio (Mw/Mw) with said branched chain amino acids between 20 and 50%, in particular with a threonine to lysine ratio in which lysine is from 10 to 50% more
25 represented than threonine.

13. Compositions, according claim 11, characterized in that said branched chain amino acids plus threonine and lysine are in a molar ratio (Mw/Mw) from 50 to 70% with histidine.

30 14. Compositions, according to claim 10, characterized in that histidine is present in molar ratio (Mw/Mw) up to 50% of the following amino acids:

 - cyst(e)ine (i.e., cystine and cysteine) and methionine, in particular in a molar ratio up to 50% of
35 histidine;

- 13 -

- phenylalanine and tyrosine, in particular in molar ratio up to 50% of histidine,

- tryptophan, in particular up to 10% of the weight of all the other amino acids, on a molar weight basis.

5 15. Compositions, according to claim 14, characterized in that cyst(e)ine is represented on a basis from 50 to 200% in molar ratio (Mw/Mw) of the amount of methionine.

10 16. Compositions, according to claim 14, characterized in that tyrosine is represented up to 50% of the molar weight of phenylalanine.

15 17. Compositions, according to claim 10, characterized by having a pH in water solution comprised between 6.5 and 8.5, with or without excipients suitable for the preparation of tablets, capsules, powders, etc., in any pharmacological form suitable for oral or parenteral use.

20 18. Compositions, according claim 10, suitable for producing an increase of the ejection fraction, both at rest and at the peak of isometric exercise.

19. Compositions, according to claim 10, suitable for producing the removal of the reduction of the ejection fraction during isometric strain which is typical for patients suffering from II type diabetes.

25 20. Compositions, according to claim 10, suitable for producing a positive action on myocardial inotropism and on contractile recruitment during conditions of increased load.

30 21. Compositions, to claim 10, suitable for producing a reduction of the extension of the reversible chronic contractile dysfunction and/or of the extension of myocardial hibernation phenomena.

35 22. Compositions, according to claim 10, suitable for reducing the extension of the contractile dysfunction induced by acute ischemia during isometric strain.